New European registry on ROP established
UK centres asked to contribute data on retinopathy of prematurity.
A European-wide registry on retinopathy of prematurity (ROP) has been established – the EU-ROP - and is seeking centres in the UK to contribute data. ROP is one of the leading causes for childhood blindness worldwide.
The EU-ROP (Clinicaltrials.gov identifier: NCT04939571) is an international, multicenter, observational registry study to collect and analyze data on infants treated for ROP irrespective of the treatment modality. The registry is strictly observational; only clinical routine data is collected, no study-specific examinations or interventions are to be performed. The EU-ROP data will help to better understand and improve ROP care and outcomes across Europe. By now (October 2022) data from 195 patients from 8 countries have been entered into the database. Further 5 countries have already obtained a positive Ethics vote and are about to start entering data.
The EU-ROP project is currently financed by extramural grants from the University Medicine Greifswald, solicited through the EU-ROP principal investigator from Novartis AG and Bayer AG.
For further information please visit the project website: www.eu-rop.org or email: [email protected]